Hyperoncotic Dextran and Systemic Aprotinin in Necrotizing Rodent Pancreatitis

References

• Klar E, Herfarth C, Messmer K. Therapeutic effect of iso-volemic hemodilution with dextran 60 on the impairment of pancreatic microcirculation in acute biliary pancreatitis. Ann Surg 1990; 211: 346–53
   PubMedGoogle Scholar
• Schmidt J, Rattner D W, Lewandrowski K, Compton C C, Knoefel W T, Warshaw AL. A better model of acute pancreatitis for evaluating therapy. Ann Surg 1992; 215: 44–56
   PubMed Web of Science ®Google Scholar
• Schmidt J, Fernandez-delCastillo C, Rattner D W, Lewandrowski K, Warshaw AL. Ultrahigh-molecular dextran solutions reduce trypsinogen activation, lower mortality and prevent acinar necrosis in acute experimental pancreatitis. Am J Surg 1993; 165: 40–5
   PubMedGoogle Scholar
• Kimura T, Zuidema G D, Cameron JL. Acute pancreatitis, experimental evaluation of steroid, albumin and trasylol therapy. Am J Surg 1980; 140: 403–8
   PubMed Web of Science ®Google Scholar
• Crocket K V, Reising J R, Wirman J A, Gau N, Joffe SN. Effect of dextran 40 and aprotinin on experimental acute pancreatitis. J Surg Res 1984; 36: 256–64
   PubMedGoogle Scholar
• Baden H, Jordal K, Lund F, Zachariae F. Prophylactic and curative action of Trasylol™ in pancreatitis, a double-blind trial. Scand J Gastroenterol 1969; 4: 291–5
   PubMed Web of Science ®Google Scholar
• Medical Research Council., Multicentre trial of glucagon and aprotinin. Death from acute pancreatitis. Lancet 1977; 2: 632–5
   PubMed Web of Science ®Google Scholar
• Medical Research Council Multicentre Trial., Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut 1980; 21: 334–9
   PubMed Web of Science ®Google Scholar
• Imrie C W, Benjamin I S, Ferguson J C, Mc Kay A J, Mackenzie I, O'Neill J, et al. A single-centre, double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978; 65: 337–41
   PubMed Web of Science ®Google Scholar
• Trapnell J E, Rigby C C, Talbot C H, Duncan E HL. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg 1974; 61: 177–82
   PubMed Web of Science ®Google Scholar
• Schmidt J, Fernandez-Del Castillo C, Rattner D W, Lewandrowski K, Compton C C, Warshaw AL. Trypsinogen-activation peptides in experimental rat pancreatitis: prognostic implications and histopathologic correlates. Gastroenterology 1992; 103: 1009–16
   PubMedGoogle Scholar
• Harris J M, West GB. Rats resistant to the dextran anaphylactoid reaction. Br J Pharmacol 1963; 20: 550–62
   Google Scholar
• Ivarsson L, Appelgren L, Rudenstam CM. Plasma volume after dextran infusion in rats sensitive and non-sensitive to dextran. Eur Surg Res 1975; 7: 315–25
   PubMedGoogle Scholar
• Mandavilli U, Schmidt J, Rattner DW., Watson WT, Warshaw AL. Continuous complete collection of uncontaminated urine in the conscious rodent. Lab Anim Sci 1991; 41: 258–61
   PubMedGoogle Scholar
• Harvey M H, Wedgwood K R, Austin J A, Reber HA. Pancreatic duct pressure, duct permeability and acute pancreatitis. Br J Surg 1989; 76: 859–62
   PubMedGoogle Scholar
• Mc Gudgeon A M, Heath D I, Hurley P, Jehanli A, Patel G, Wilson C, et al. Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis. Lancet 1990; 335: 4–8
   PubMedGoogle Scholar
• Hurley P R, Cook A, Austen B M, Hermon-Taylor J. Antibodies to trypsinogen activation peptides recognize both Ca+ + dependent and Ca++ independent epitopes. Biochem Soc Trans 1988; 16: 337–8
   Google Scholar
• Hurley P R, Cook A, Jehanli A, Austen B M, Hermon-Taylor J. Development of radioimmunoassays for free tetra-L-aspartyl-L-lysine trypsinogenactivation peptides (TAP). J Immunol Meth 1988; 111: 195–203
   PubMedGoogle Scholar
• Schmidt J, Lewandrowski K, Fernandez-del Castillo C, Rattner D W, Mandavilli U, Compton C C, et al. Histopathologic correlates of elevated serum amylase in experimental pancreatitis. Dig Dis Sci 1992; 37: 1426–33
   PubMedGoogle Scholar
• Fernandez-del Castillo C, Schmidt J, Rattner D W, Lewandrowski K, Compton C C, Jehanli A, et al. Generation and possible significance of trypsinogen activation peptides in experimental acute pancreatitis in the rat. Pancreas 1992; 7: 263–70
   PubMedGoogle Scholar
• Schmidt J, Lewandrowski K, Rattner D W, Mandavilli U, Compton C C, Warshaw AL. Morphometric characteristics and homogeneity of a new model of acute experimental pancreatitis in the rat. Int J Pancreatol 1992; 12: 41–51
   PubMedGoogle Scholar
• Knol J A, Edgcomb L P, Inman M G, Eckhauser FE. Low molecular weight dextran in experimental pancreatitis: effects on pancreatic microcirculation. J Surg Res 1983; 35: 73–82
   PubMed Web of Science ®Google Scholar
• Klar E, Endrich B, Messmer K. Microcirculation of the pancreas. A quantitative study of physiology and changes in pancreatitis. Int J Microcirc Clin Exp 1990; 9: 85–101
   PubMedGoogle Scholar
• Kelly D M, Mc Entee G P, Delaney C, Mc Geeney K F, Fitzpatrick JM. Temporal relationship of acinar and micro vascular changes in caerulein-induced pancreatitis. Br J Surg 1993; 80(1)174–6
   Google Scholar
• Popper H L, Necheles H, Russel KC. Transition of pancreatic edema into pancreatic necrosis. Surg Gynecol Obstet 1948; 87: 79–82
   PubMedGoogle Scholar
• Anderson MC. Venous stasis in the transition of edematous pancreatitis to necrosis. JAMA 1963; 183: 534–7
   PubMedGoogle Scholar
• Klar E, Rattner D W, Compton C, Stanford G, Chernow B, Warshaw AL. Adverse effect of therapeutic vasoconstrictors in experimental acute pancreatitis. Ann Surg 1991; 214: 168–74
   PubMedGoogle Scholar
• Sanfey H, Cameron JL. Increased capillary permeability: an early lesion in acute pancreatitis. Surgery 1984; 96: 485–91
   PubMed Web of Science ®Google Scholar
• Klar E, Messmer K, Warshaw A L, Herfarth C. Pancreatic ischaemia in experimental acute pancreatitis: mechanism, significance and therapy. Br J Surg 1990; 77: 1205–10
   PubMed Web of Science ®Google Scholar
• Goodhead B. Acute pancreatitis and pancreatic blood flow. Surg Gynecol Obstet 1969; 129: 331–40
   PubMedGoogle Scholar
• Donaldson L A, Williams R W, Schenk WG. Experimental pancreatitis: effect of plasma and dextran on pancreatic blood flow. Surgery 1978; 84: 313–21
   PubMed Web of Science ®Google Scholar
• Klar E, Mall G, Messmer K, Ch Herfarth, Rattner D W, Warshaw AL. Improvement of impaired pancreatic microcirculation by isovolemic hemodilution protects pancreatic morphology in acute biliary pancreatitis. Surg Gynecol Obstet 1993; 176: 144–50
   PubMedGoogle Scholar
• Schmidt J, Huch K, Sinn H P, Mithoefer K, Klar E, Warshaw A L, et al. Effect of hyperoncotic dextrans after delayed onset of therapy in acute experimental pancreatitis. Gastroenterology 1993; 104: A334
   Google Scholar
• Messmer K, Kreimeier U, Hammersen F. Microcirculation in circulatory disorders. Multiple organ failure: clinical implications to macro-and microcirculation, H Manabe, B W Zweifach, K Messmer. Springer, New York 1988; 147–57
   Google Scholar
• Mishler JM. Synthetic plasma volume expanders—their pharmacology, safety and clinical efficacy. Clin Haematol 1984; 13: 75–92
   PubMedGoogle Scholar
• Nolte D, Lehr H A, Messmer K. Dextran and adenosine-coupled dextran reduce postischemic leukocyte adherence in post-capillary venules of the hamster. Prog Appl Microcirc 1991; 10: 103–11
   Google Scholar
• Kraut H, Koerbel I, Scholtan W, Schultz F. Versuche zur Isolierung des Kallikrein-Inaktivators. Hoppe-Seylers Z Physiol Chem 1960; 321: 90–6
   PubMedGoogle Scholar